PTCT•benzinga•
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
Summary
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga